NOVAVAX INC (NVAX): restructuring charge — Novavax Q1 revenue $81M, net loss $294M; cuts 25% workforce, positive Phase 2 combo vaccine data

NOVAVAX INC

2023-Q1 EPS reported -$3.41 revenue$80,951,000

Q1 revenue $81M vs $704M YoY, net loss $294M vs net income $203M; includes $65M revenue reversal.
Announced 25% global workforce reduction (20% FTEs) to cut 2024 R&D+SG&A by 40-50% vs 2022; one-time charges $10-15M.
Positive Phase 2 data for COVID-Influenza Combination, standalone influenza, and high-dose COVID vaccines; all well-tolerated with robust immune responses.
FY2023 revenue guidance $1.4-1.6B; combined R&D+SG&A $1.3-1.4B (excl. restructuring).
Cash $637M at Mar 31, down from $1.3B at Dec 31; reduced current liabilities by $541M including $325M convertible debt maturity.

item 2.02 item 2.05 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

NOVAVAX INC reported first quarter ended March 31, 2023 results: revenue $81 million, net income $294 million.

Period: first quarter ended March 31, 2023
Revenue: $81 million
Net income: $294 million
Result: reported results

Exact text from the filing

First Quarter 2023 Financial Results • Total revenue: Due to an emerging seasonal demand pattern for COVID vaccines, total revenue for the first quarter of 2023 was $81 million compared to $704 million in the same period in 2022. First quarter 2023 product sales include a $65 million revenue reversal associated with doses delivered in 2022 that are scheduled for future replacement. • Cost of sales for the first quarter of 2023 were $34 million, compared to $15 million in the same period in 2022. This includes $20 million related to excess, obsolete, or expired inventory and losses on firm purchase commitments. • Research and development expenses (R&D) for the first quarter of 2023 were $247 million, compared to $383 million in the same period in 2022. The decrease was primarily due to a reduction in clinical and manufacturing spend. • Selling, general and administrative expenses (SG&A) for the first quarter of 2023 were $113 million, compared to $96 million for the same period in 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

NOVAVAX INC reported full year 2023 results: revenue $1.4 and $1.6 billion. Guidance initiated.

Period: full year 2023
Revenue: $1.4 and $1.6 billion
Guidance: initiated
Result: guidance update

Exact text from the filing

Provided full year 2023 total revenue guidance of between $1.4 and $1.6 billion

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

NOVAVAX INC announced a restructuring with charges of approximately $10 million to $15 million (approximately 25% reduction of its global workforce).

Type: restructuring
Charge: approximately $10 million to $15 million
Headcount: approximately 25% reduction of its global workforce

Exact text from the filing

On May 8, 2023, the Board of Directors of the Company approved an approximately 25% reduction of its global workforce, comprised of an approximately 20% reduction in the Company’s full-time employees and the remainder comprised of contractors and consultants. The Company expects the full annual impact of the cost savings to be realized in 2024 and approximately half of the annual impact, excluding one-time charges, to be realized in 2023 due to timing of implementing the measures, and the applicable laws, regulations, and other factors in the jurisdictions in which it operates. The Company is expected to record a charge of approximately $10 million to $15 million related one-time employee severance and benefit costs, the majority of which is expected to be incurred in the second quarter of 2023 and it is evaluating the anticipated cost related to the consolidation of facilities and infrastructure.

View on SEC.gov

41 earnings releases filed in the last 30 days. Browse all earnings releases →

NOVAVAX INC filing history →

Source: SEC EDGAR

accession 0001000694-23-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.